ArticleProstate cancer and prostatic diseases2005
MUC1 expression in human prostate cancer cell lines and primary tumors.
Article in Prostate cancer and prostatic diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 60 citations in OpenAlex.
- Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer.Nature communications · 2025Article
- E2F4 Promotes Malignant Behaviors of Prostate Cancer Through Activating MUC1 Expression Transcriptionally.Asia-Pacific journal of clinical oncology · 2025Article
- Measuring the multifaceted roles of mucin-domain glycoproteins in cancer.Advances in cancer research · 2023Review
- MUC1: The First Respiratory Mucin with an Anti-Inflammatory Function.Journal of clinical medicine · 2017Review
- Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?Frontiers in oncology · 2017Review
- MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.Prostate cancer and prostatic diseases · 2016Article
- MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.PloS one · 2016Article
- Roles and regulation of the mucus barrier in the gut.Tissue barriers · 2015Article
- Antiinflammatory role of MUC1 mucin during infection with nontypeable Haemophilus influenzae.American journal of respiratory cell and molecular biology · 2012Article
- Transmembrane mucins as novel therapeutic targets.Expert review of endocrinology & metabolism · 2011Article
- Molecular Validation of PACE4 as a Target in Prostate Cancer.Translational oncology · 2011Article
- O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro.PloS one · 2011Article
- MUC1 as a Putative Prognostic Marker for Prostate Cancer.Biomarker insights · 2008Article
- MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden.British journal of cancer · 2007Article
- Mucin gene expression in human male urogenital tract epithelia.Human reproduction (Oxford, England) · 2006Article
- Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer.Clinical & experimental metastasis · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
MUC1 expression was evaluated in normal prostate epithelial cells (PrEC), and prostate cancer cell lines in response to dihydrotestosterone (DHT), interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) treatment. Expression of MUC1 core protein was stimulated in PrEC and PC-3 cells after cytokine treatment, but was highly and constitutively expressed by DU-145 cells. MUC1 was not expressed by LNCaP, C4-2 or C4-2B cells under any condition. DHT alone or in combination with cytokines had no effect on MUC1 expression in any cell line tested. Using antibodies capable of detecting all isoforms of MUC1 core protein independent of their glycosylation state, immunohistochemical staining of tissue microarrays containing both nontumor and tumor tissue revealed that only 17% of tumor tissues and 41% of nontumor tissues stained positively for MUC1. Staining patterns in tumor tissue varied from focal apical staining to diffuse cytoplasmic staining. Neither the presence of MUC1 core protein nor its subcellular distribution correlated with Gleason grade. These data indicate that MUC1 is a poor marker of prostate cancer progression. Furthermore, IFN-gamma and TNF-alpha strongly induce MUC1 expression in both normal prostate epithelia and certain prostate tumor cell lines and may exacerbate pathologies associated with MUC1-positive prostate cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.